The emerging diversity of neuromuscular junction disorders
- PMID: 17915563
- PMCID: PMC2949330
The emerging diversity of neuromuscular junction disorders
Abstract
Research advances over the last 30 years have shown that key transmembrane proteins at the neuromuscular junction are vulnerable to antibody-mediated autoimmune attack These targets are acetylcholine receptors (AChRs) and muscle specific kinase (MuSK) in myasthenia gravis, voltage-gated calcium channels (VGCCs) in the Lambert-Eaton myasthenic syndrome (LEMS), and voltage-gated potassium channels (VGKCs) in neuromyotonia. In parallel with these immunological advances, mutations identified in genes encoding pre-synaptic, synaptic and postsynaptic proteins that are crucial to neuromuscular transmission have revealed a similar diversity of congenital myasthenic syndromes (CMS). These discoveries have had a major impact on diagnosis and management.
Figures
References
-
- Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871-2. - PubMed
-
- Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9. - PubMed
-
- Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977;296:125-31. - PubMed
-
- Pinching AJ, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma-exchange. Lancet 1976;2:1373-6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical